The lancet oncology
-
The lancet oncology · Dec 2024
ReviewNavigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health.
The translation of basic drug discoveries from laboratories to clinical use presents substantial challenges. Factors such as insufficient funding, misdirected project focus, and inability to understand a drug's limitations or strengths contribute to the difficulty of this process. To address these issues, the National Institutes of Health (NIH) has established various resources dedicated to streamlining drug development. ⋯ The NIH also provides access to key resources through various programmes, such as the Developmental Therapeutics Program, focusing on preclinical drug discovery and the Cancer Therapy Evaluation Program, which oversees clinical trial efforts for investigational agents. These resources might include funding opportunities, access to a network of scientific experts, and services to address gaps in scientific work. This Review explores the diverse platforms and resources available at the NIH and outlines how researchers can leverage them to expedite the drug development process.
-
The lancet oncology · Dec 2024
The current and future global burden of cancer among adolescents and young adults: a population-based study.
Compared with children and older adults, the burden of cancer in adolescents and young adults (ages 15-39) is understudied. We aimed to quantify the global burden of adolescent and young adult cancer in 2022 and 2050, and explore patterns in incidence, mortality, and case fatality. ⋯ None.